Properly Manage the New Inhaled Levodopa (Inbrija) on Admission

June 2019

Inbrija (in-BREE-jah) will be the first INHALED levodopa for adults with Parkinson's disease.

It's an on-demand levodopa that starts to work in about 10 minutes and lasts about an hour. It's used PRN to treat "off" episodes...when scheduled carbidopa/levodopa wears off between doses and symptoms return.

Patients will still need scheduled carbidopa/levodopa...and may also use add-ons, such as dopamine agonists (pramipexole, etc), MAO-B inhibitors (rasagiline, etc), or COMT inhibitors (entacapone, etc).

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Ulcerative Colitis Update Your Acute Ulcerative Colitis Protocols With the Latest Evidence
Sepsis Weigh Options When Choosing Pressors for Septic Shock
Antithrombotics Balance Risks and Benefits of Antithrombotic Combos in Atrial Fib
Pregnancy Expedite Treatment for Women With Severe Gestational Hypertension
Cannabinoids Be Prepared With Answers About CBD
Migraine Lean Toward Prochlorperazine for Acute Pediatric Migraines
Opioids Facilitate Opioid Tapers During Transitions of Care
Parkinson's Disease Properly Manage the New Inhaled Levodopa (Inbrija) on Admission
Insomnia Explain Risk of Strange Sleep Behaviors With "Z-Drugs"

Properly Manage the New Inhaled Levodopa (Inbrija) on Admission

Get unlimited access through an Enterprise license

Table of Contents